Kamada (NASDAQ: KMDA)
Kamada Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Kamada Company Info
Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.
News & Analysis
Kamada Will Supply COVID-19 Treatment to Israel
The biotech specializes in plasma-derived protein therapeutics.
2 Coronavirus Treatment Stocks to Buy Right Now
Eli Lilly and Kamada are two of the most intriguing companies working on this part of the COVID-19 problem.
What You Need to Know About the "Breakthrough" Coronavirus Therapy Heralded by President Trump
Convalescent plasma holds promise for treating COVID-19, but it's still unproven.
Why ADMA Biologics, iBio, and Kamada Are Jumping Today
The FDA's emergency use authorization of convalescent plasma therapy is sending these three stocks higher today.
The 1 Promising Coronavirus Stock No One Knows About Yet
Kamada might be the least well-known biotech company working on a COVID-19 treatment right now.
Kamada Ltd. (KMDA) Q1 2019 Earnings Call Transcript
KMDA earnings call for the period ending March 31, 2019.
Valuation
Earnings Transcripts
Kamada Ltd (KMDA) Q3 2020 Earnings Call Transcript
KMDA earnings call for the period ending September 30, 2020.
Kamada Ltd (KMDA) Q2 2020 Earnings Call Transcript
KMDA earnings call for the period ending June 30, 2020.
Kamada Ltd (KMDA) Q1 2020 Earnings Call Transcript
KMDA earnings call for the period ending March 31, 2020.
Kamada Ltd (KMDA) Q4 2019 Earnings Call Transcript
KMDA earnings call for the period ending December 31, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.